MRNA ▼ -2.3% - Moderna, Inc. $MRNA d/g Sell @ Redburn pt 81 The firm calls the Phase 3 melanoma vaccine result “a great result,” but says the stock now appears to price in broad use across multiple tumor types where there is still little or no supporting data Moderna shares fell 2.3% after Redburn downgraded the stock to Sell with a $81 price target, arguing that while the Phase 3 melanoma vaccine result was strong, the current valuation already assumes successful adoption across multiple cancer types where clinical evidence remains limited or absent. 03-SEP-2026 05:16 AM ET